<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01391260</url>
  </required_header>
  <id_info>
    <org_study_id>CS-S10-09</org_study_id>
    <nct_id>NCT01391260</nct_id>
  </id_info>
  <brief_title>Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>A Phase II Trial of Radiation Therapy Combined With Iressa in Patients With Locally Advanced Non-small Cell Lung Cancer With Harboring Active EGFR Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ZhuGuangYing</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Renmin Hospital of Wuhan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>307 Hospital of PLA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Clinical Service Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ZhuGuangYing</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to access the effect and safety of radiotherapy combined whth
      Iressa for patients with locally advanced non-small cell lung cancer with harboring active
      EGFR mutations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Worldwide more than half a million new cases of lung cancer are diagnosed annually. About 80%
      of these tumours are of non-small cell histological type. Surgery is the treatment of choice,
      but only about 20% of tumours are suitable for potentially curative resection. Concurrent
      chemoradiotherapy is the standard treatment for locally advanced NSCLC. When Iressa was used
      in the first-line treatment of advanced NSCLC with EGFR mutations positive, the 12-month
      rates of progression-free survival were 24.9%. Therefore, we speculate that the EGFR
      mutations in patients with locally advanced NSCLC, Gefitinib combined with radiotherapy may
      be better than chemoradiotherapy. We design the study to access the effect and safety of
      radiotherapy combined whth Iressa for patients with locally advanced non-small cell lung
      cancer with harboring active EGFR mutations.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate (RR)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (MD-Anderson questionnaire)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Radiotherapy Combined With Gefitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Gefitinib</intervention_name>
    <description>Radiation Therapy: 3D-CRT/IMRT 95%PTV 60-66Gy, 1.8-2.0Gy/f,5f/w; Gefitinib: 250 mg, Qd, p.o;</description>
    <arm_group_label>Radiotherapy Combined With Gefitinib</arm_group_label>
    <other_name>Iressa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of non-squamous NSCLC; Stage ⅢA-ⅢB(not suitable for
             surgery) or stage Ⅳ(only single-site single transfer );

          -  Untreated patients, or who completed ≤ 2 cycles of first-line chemotherapy
             (chemotherapy regimen: paclitaxel, docetaxel + cisplatin) within the previous month;

          -  Patients with tumor EGFR mutation positive (exon 19 deletion mutation or exon 21 L858R
             substitution mutation);

          -  Patients must be informed of the investigational nature of the study and must sign an
             informed consent form;

          -  Presence of at least one measurable/evaluable according to RECIST criteria.

          -  ECOG performance Status 0-2 ;

          -  Patients must have a life expectancy &gt; 12 weeks;

          -  Patients with laboratory values as follows:WBC＞4.0 x 109/L; ANC≥1.5 x 109/L; PLT≥100 x
             109/L; HGB≥10 g/dL; CR≤1.5 x ULN; TBIL＜1.5 x ULN; AST and ALT≤1.5 x ULN; LDH≤1.5 x
             ULN; AKP≤5 x ULN;

          -  FEV 1≥1.0L and ＞50% Corresponding normal values;

          -  Patient candidate to standard platinum-based chemotherapy;

          -  Patients must be nonpregnant and non-lactating.Patients of childbearing potential must
             implement an effective method of contraception during the study. All female Patients,
             except those who are postmenopausal or surgically sterilized, must have a negative
             pre-study serum or urine pregnancy test.

        Exclusion Criteria:

          -  Any evidence of clinically active interstitial lung disease;

          -  Diagnosis of any other malignancy during the last 5 years, except for in situ
             carcinoma of cervix uterine and squamous cell carcinoma of the skin；

          -  Pregnancy or lactating；

          -  Serious concomitant infection;

          -  MI within preceding 6 months or symptomatic heart disease, including unstable angina,
             congestive heart failure or uncontrolled arrhythmia;

          -  As judged by the investigator, any evidence of severe or uncontrolled systemic disease
             (eg, unstable or uncompensated respiratory, cardiac, hepatic, or renal disease);

          -  Patients who are not suitable to participate in the trial according to researchers.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhu Guangying</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yu Rong</last_name>
    <email>yurong311@yahoo.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>307 Hosptial of PLA</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ge Shen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chinese Academy of Medical Sciences Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>266000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lvhua Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renmin Hospital of Wuhan University, Hubei General Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Qibin Song</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Min Fan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Shenglin Ma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guangying Zhu</last_name>
      <email>zgypu@yahoo.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Rong Yu</last_name>
      <email>yurong311@yahoo.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Guangying Zhu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2011</study_first_submitted>
  <study_first_submitted_qc>July 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2011</study_first_posted>
  <last_update_submitted>August 1, 2011</last_update_submitted>
  <last_update_submitted_qc>August 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>Zhu Guangying</name_title>
    <organization>Beijing Cancer Hospital</organization>
  </responsible_party>
  <keyword>Locally Advanced NSCLC</keyword>
  <keyword>EGFR Mutation Positive</keyword>
  <keyword>Radiotherapy combined Gefitinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

